MedTrace Logo

Early Detection of Broken Hearts in Cancer Patients

NCT02086695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2016-01-29

No results posted yet for this study

Summary

The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or administer prophylactic cardioprotective agents, prior to the development of irreversible cardiac dysfunction. We hypothesize that cardiac biomarkers, TVI/strain-derived indices will be able to accurately detect subtle cardiac injury at a time when conventional Left Ventricular Ejection Fraction (LVEF) remains normal in BVZ or Sunitinib mediated cardiotoxicity. Additionally, we hypothesize that Endothelial Function Test (EndoPAT) testing can detect early BVZ or Sunitinib mediated endothelial dysfunction.

Conditions

Sponsors & Collaborators

  • The Asper Foundation

    collaborator UNKNOWN

  • St. Boniface Hospital

    collaborator OTHER

  • Lantheus Medical Imaging

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02086695 on ClinicalTrials.gov